4D Molecular Therapeutics (NASDAQ: FORTH) is an American biotechnology company headquartered in Emeryville, California, focused on developing precision gene therapies using its proprietary adeno-associated virus (AAV) vector platform. Founded in 2012 by Dr. David Kirn and Dr. Charles Gersbach, 4DMT has raised over $740 million in funding and established strategic partnerships with major pharmaceutical companies["@d2026"].
4D Molecular Therapeutics (NASDAQ: FORTH) is an American biotechnology company headquartered in Emeryville, California, focused on developing precision gene therapies using its proprietary adeno-associated virus (AAV) vector platform. Founded in 2012 by Dr. David Kirn and Dr. Charles Gersbach, 4DMT has raised over $740 million in funding and established strategic partnerships with major pharmaceutical companies["@d2026"].
The company's name "4D" refers to its four-dimensional approach to vector engineering: considering tissue targeting, route of delivery, immune profile, and manufacturing scalability simultaneously. This sophisticated approach distinguishes 4DMT from traditional AAV development approaches that optimize for a single parameter["@kirn2019"].
4DMT has demonstrated consistent growth through multiple funding rounds:
| Year | Event | Amount | Details |
|------|-------|--------|---------|
| 2014 | Series A | $10M | Initial seed funding for platform development |
| 2017 | Series B | $40M | Expanded R&D capabilities |
| 2019 | Series C | $95M | Advanced clinical programs |
| 2020 | Series D | $112M | Pre-IPO funding |
| 2021 | IPO | $168M | NASDAQ: FORTH |
| 2023 | Follow-on | $75M | Pipeline expansion |
The company maintains a strong financial position with a market capitalization of approximately $200 million as of 2025 and a cash runway extending into 2027[@d2026].
| Attribute | Details |
|-----------|---------|
| Headquarters | Emeryville, California, USA |
| Founded | 2012 |
| Ticker | NASDAQ: FORTH |
| CEO | Dr. David Kirn |
| Market Cap | ~$200M (2025) |
| Employees | ~200 |
| Founded By | Dr. David Kirn, Dr. Charles Gersbach |
4DMT's proprietary RGD platform represents a sophisticated approach to AAV vector engineering that combines directed evolution, rational design, and high-throughput screening to develop optimized gene delivery vehicles[@kirn2019].
The platform enables:
4DMT's technology addresses key limitations of first-generation AAV vectors:
| Challenge | 4DMT Solution |
|-----------|---------------|
| Limited tissue tropism | Engineered capsids with enhanced target tissue transduction |
| Pre-existing immunity | Variants that evade neutralizing antibodies |
| Delivery route limitations | Vectors optimized for specific administration routes |
| Manufacturing scalability | Suspension cell culture production system |
The company focuses on engineering AAV vectors with multiple optimized properties[@zincarelli2018]:
| Feature | Description |
|---------|-------------|
| Tissue specificity | Enhanced transduction of target tissues through engineered capsids |
| Route optimization | Vectors optimized for specific delivery routes (IV, intravitreal, inhalation) |
| Manufacturing scalability | Suspension cell culture production for commercial scale |
| Reduced immunogenicity | Evasion of neutralizing antibodies for repeat dosing |
4DMT has developed a robust pipeline targeting retinal diseases[@calton2024]:
| Program | Target | Indication | Development Stage | Route |
|---------|--------|------------|-------------------|-------|
| 4D-150 | VEGF + Ang2 | Wet AMD | Phase 3 | Intravitreal |
| 4D-150 | VEGF | Diabetic Macular Edema (DME) | Phase 1/2 | Intravitreal |
| 4D-175 | Complement | Geographic Atrophy | Preclinical | Intravitreal |
| 4D-310 | GLA | Fabry Disease Cardiomyopathy | Phase 1/2 | Intravitreal |
4D-150 is a dual-transgene intravitreal gene therapy for neovascular retinopathies. The Phase 1/2 trial demonstrated robust efficacy with patients maintaining vision gains at 12 months post-treatment[@calton2024]. The Phase 3 program is actively enrolling.
4D-310 delivers a functional copy of the GLA gene to treat Fabry disease cardiomyopathy, a genetic disorder caused by alpha-galactosidase A deficiency. The Phase 1/2 trial is evaluating safety and biomarker endpoints.
4DMT's aerosol delivery platform enables gene therapy for lung diseases[@calton2025]:
| Program | Target | Indication | Development Stage | Route |
|---------|--------|------------|-------------------|-------|
| 4D-710 | CFTR | Cystic Fibrosis | Phase 1/2 | Inhalation |
| 4D-725 | AAT | Alpha-1 antitrypsin deficiency | Preclinical | Inhalation |
4D-710 is an aerosolized AAV gene therapy delivering a functional CFTR gene to lung epithelial cells. Preclinical data demonstrated significant CFTR expression in relevant cell types, and the Phase 1/2 trial is evaluating safety and efficacy[@calton2025].
While 4DMT has not yet advanced CNS programs into clinical development, the company has published research on brain delivery and maintains scientific capabilities in this area[@vadakkan2019][@meng2019].
The company's CNS research focuses on:
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| 4D-C102 | CNS target | Alzheimer's disease | Discovery |
| 4D-C105 | Neuroinflammation | Parkinson's disease | Discovery |
| 4D-C110 | Tau pathology | Alzheimer's disease | Discovery |
4DMT's CNS programs remain in discovery, focusing on identifying optimal capsids for brain delivery and validating therapeutic targets for neurodegenerative diseases[@kotterman2014][@rayner2019].
4DMT has established partnerships with major pharmaceutical companies:
| Partner | Focus Area | Deal Value |
|---------|------------|------------|
| Pfizer | Pulmonary gene therapy | $250M+ |
| Roche | CNS programs | Via Spark acquisition |
| Novartis | Ophthalmic options | Option fees |
| Janssen | Retinal diseases | Development funding |
The partnership with Pfizer focuses on developing AAV vectors for pulmonary diseases, leveraging 4DMT's RGD platform for targeted lung delivery. This collaboration validates the company's technology platform and provides non-dilutive funding for pipeline development.
4DMT competes in the AAV gene therapy space:
| Company | Strengths | Weaknesses |
|---------|------------|------------|
| BioMarin | Approved gene therapies (Roctavian) | Limited CNS capability |
| Spark Therapeutics/Roche | Luxturna approved, global reach | Focus on ocular |
| uniQure | Hemgenix approval, manufacturing | Single product focus |
| Pfizer | Global reach, pipeline investment | In-house AAV development |
| Regenxbio | NAV vectors, multiple partnerships | Manufacturing challenges |
| Spark | First FDA-approved retinal gene therapy | Limited pipeline diversity |
4DMT's differentiation lies in its proprietary RGD platform, which enables systematic optimization of capsid properties for specific tissues and routes of delivery.
4DMT's research has been published in leading peer-reviewed journals:
4DMT's pipeline expansion strategy includes: